Background {#Sec1}
==========

Low-density lipoprotein cholesterol (LDL-C) serum concentrations correlate with cardiovascular (CV) risk and lowering of LDL-C reduces CV events. Based on many large randomized clinical studies, LDL-C lowering with statins is recommended for the secondary prevention of cardiovascular outcomes \[[@CR5], [@CR33], [@CR36]\]. The current European guidelines (issued 2011 by EAS/ESC) \[[@CR33]\] as well as the US guidelines \[[@CR36]\] (issued 2013 by AHA/ACC) on the treatment of hyperlipidaemia pose particular emphasis on patients with very high cardiovascular risk and recommend stringent LDL-C lowering with statins. While the US guidelines recommend fixed high doses (e.g,. atorvastatin 80 mg) for high-risk individuals \[[@CR36]\], the European guidelines recommend a treatment goal of LDL-C \<70 mg/dL or a \>50 % LDL-C reduction \[[@CR33]\].

According to a recent German study in primary care, the prevalence of diagnosed coronary heart disease (CHD) is 12 %, and of diabetes mellitus type 2 (DM) 15 % \[[@CR31]\]. Both diseases often present concomitantly \[[@CR31]\]. Patients with either CHD or DM (and those with stroke, peripheral arterial disease or chronic renal insufficiency) are at very high risk and can especially benefit from lipid lowering \[[@CR33]\].

The utilization of statins in Germany increased steadily in the recent years, up to 1707 million daily doses in 2013 for all statins combined \[[@CR17]\]. Because of its designation as lead substance within this group in 2006, simvastatin was most widely prescribed in the past. However, since introduction of atorvastatin as generic drug in March 2013, for this agent 250 million daily doses were administered, with further increase anticipated \[[@CR17]\]. Among the generic statins, atorvastatin is perceived as the most potent agent and atorvastatin will likely be the most frequently prescribed statin in the near future \[[@CR13], [@CR20], [@CR27]\].

Despite the increasing use of atorvastatin, current information on the drug under clinical practice conditions is limited compared to evidence on simvastatin in this setting \[[@CR11], [@CR37]\] Against this background, the cross-sectional study DISCOVER was initiated to assess the standard of care in ambulatory patients at very high cardiovascular risk, treated with atorvastatin monotherapy (original drug or generics).

Methods {#Sec2}
=======

DISCOVER was performed as retrospective, cross-sectional study in the offices of 539 physicians in all regions of Germany between June and December 2014. Study materials were approved by the ethics committee of the Bavarian Physicians Chamber in Munich on 8 May 2014. DISCOVER was registered in the vfa study database (No. 931). Cardiologists, diabetologists, internists and general practitioners agreed to enter data of up to first five eligible patients into the electronic case collection form.

Patients were eligible for documentation if they met the following criteria:≥18 years of age at the documentation visit;diagnosed CHD, diagnosed DM, or both conditions concomitantly (CHD + DM);current treatment with atorvastatin, stable for at least 1 month;LDL-C laboratory value available.

Patients on other lipid-lowering therapies were not eligible. The following data were collected: age, gender, weight, height, and waist circumference, health insurance status (statutory or private), index diagnoses (DM, CHD), smoking, arterial hypertension, cardiovascular events in the patient history (myocardial infarction, stroke, and transient ischaemic attack), previous cardiac interventions \[e.g., percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG)\].

Atorvastatin therapy was documented with the current daily dose (mg/day), the treatment duration and the daily dose at the start of the treatment. Concomitant medication for the treatment of CHD and DM was also recorded. Further information on other statins or other lipid-lowering drugs used in the past was documented.

Systolic and diastolic blood pressure values were recorded, as were laboratory values to assess blood fasting glucose and HbA~1c~ in diabetic patients, and lipid values (total cholesterol, LDL-C, HDL-C, triglycerides) in all patients. Physicians assessed the lipid-lowering target achievement on atorvastatin treatment (yes/no), and the satisfaction with current lipid-lowering treatment with atorvastatin (yes/no).

A quality management system was implemented and standard operating procedures (SOPs) were used to ensure that the study was conducted and data were generated, documented, and reported in compliance with the protocol.

Upon submission of data, each investigator verified all recorded data to be accurate. Additionally, queries were generated by data management during and after the study to resolve any questions and implausible data. Implausible data that could not be clarified were deleted from the database. For the analysis, missing values were not replaced. The entries "unknown" and "not collected" were treated like missing values.

Statistical methods {#Sec3}
-------------------

Categorical variables were shown as absolute and adjusted relative frequencies including the number of missing values in each category. Continuous variables were to be presented as means with standard deviation, median, quartiles, minimum value and maximum value, and number of known values. The statistical analysis system (SAS) software package, release 9.2 (Cary, NC, U.S.A.) was used.

Results {#Sec4}
=======

Physicians {#Sec5}
----------

A total of 539 physicians contributed to the study. The majority (*n* = 418; 78 %) documented five patients. Of the 2625 patients included, 1699 visited the office of a general practitioner, 687 an internist, 175 patients a cardiologist, and 221 a diabetologist (some physicians had more than one specialization).

Characteristics {#Sec6}
---------------

Characteristics are shown in Table [1](#Tab1){ref-type="table"}. 1233 patients had CHD (47.0 %), 658 patients DM (25.1 %), and 734 CHD plus DM (27.9 %). The mean age of the patients was 66.1 ± 10.8 years (range 19.0--93.0 years). Males were more frequently included than females (62.1 versus 37.9 %). The majority of patients were in the statutory health insurance (89.6 %), while a smaller share had private insurance (10.4 %).Table 1Demographic characteristics, comorbidities and risk factorsParameterSubgroup*P* valueTotal\
*N* = 2625CHD\
*N* = 1233DM\
*N* = 658CHD + DM\
*N* = 734Age (years)*n* = 2622*n* = 1232*n* = 658*n* = 732\<0.001^a^Mean ± SD66.1 ± 10.865.8 ± 11.063.8 ± 10.968.7 ± 9.9Range19.0--93.019.0--93.033.0--92.036.0--93.0Sex, *n* (%)*n* = 2625*n* = 1233*n* = 658*n* = 734\<0.001^b^ Male1630 (62.1)818 (66.3)329 (50.0)483 (65.8) Female995 (37.9)415 (33.7)329 (50.0)251 (34.2)Body mass index (kg/m^2)^24221108617697\<0.001^a^Mean ± SD28.9 ± 4.727.5 ± 3.930.1 ± 5.429.9 ± 4.7Arterial hypertension, *n* (%)2198 (86.6)987 (83.7)526 (82.6)685 (94.7)\<0.001^a^Family history of CHD, *n* (%)1073 (60.7 %)542 (63.6)202 (45.7)329 (69.6)Previous MI, *n* (%)853 (34.1)487 (41.9)21 (3.4)345 (48.3)Previous PCI, *n* (%)900 (36.3)547 (47.5)13 (2.1)340 (48.3)Previous CABG, *n* (%)351 (14.0)203 (17.4)10 (1.6)138 (19.4)Microalbuminuria, *n* (%)311 (14.2)23 (2.4)108 (18.5)180 (27.5)\<0.001^a^Previous stroke, *n* (%)159 (6.4)68 (5.9)35 (5.6)56 (7.9)\<0.001^a^Previous TIA, *n* (%)180 (7.2)83 (7.2)26 (4.2)71 (10.0)\<0.001^a^Values are *n* (%) if not stated otherwise*CABG* coronary artery bypass graft, *CHD* coronary heart disease, *DM* diabetes mellitus, *SD* standard deviation*P* values were calculated by ^a^ Kruskal--Wallis test or ^b^ Chi-square test

Treatment {#Sec7}
---------

Atorvastatin was administered in a wide dosing range up to 80 mg/day. The mean dose at therapy initiation was 24.8 ± 15.2 mg/day, and at the time of documentation 27.9 ± 15.8 mg/day, with no major differences between the groups (CHD 28.6 ± 16.3 mg/day, DM 24.6 ± 13.3 mg/day, CHD + DM 29.8 ± 16.4 mg/day). The 10, 20, 40 and 80 mg/day atorvastatin doses were administered in 15.6, 45.7, 33.9, and 4.8 % of the patients, respectively, without relevant differences across subgroups. Mean treatment duration was 92.6 ± 109.6 weeks (range 4--886 weeks) before the documentation date, with no major differences between treatment groups. There was no association between the atorvastatin dose (neither at initiation of therapy or at documentation) and the treatment duration.

Laboratory values and blood pressure {#Sec8}
------------------------------------

The mean value for LDL-C was 116.3 ± 42.6 mg/dl, for total cholesterol 194.5 ± 50.6 mg/dl, for HDL-C 52.2 ± 17.7 mg/dl, and for triglycerides 172.4 ± 101.0 mg/dl. As shown in Table [2](#Tab2){ref-type="table"}, TC and LDL-C were somewhat lower in the CHD + DM group, HDL-C was higher and triglycerides were lower in the CHD group. Patients in the DM group exhibited higher TC, LDL-C, and triglyceride values compared to the other groups.Table 2Lipid values, blood pressure and blood glucoseMeasurementSubgroup*P* valueTotal\
*N* = 2625CHD\
*N* = 1233DM\
*N* = 658CHD + DM\
*N* = 734Total cholesterol, mg/dL*n* = 2499*n* = 1157*n* = 631*n* = 711\<0.001194.6 ± 50.6194.1 ± 50.1203.4 ± 50.7187.5 ± 50.1LDL-C, mg/dL*n* = 2612*n* = 1227*n* = 653*n* = 732\<0.001116.3 ± 42.6115.8 ± 41.0123.9 ± 44.4110.2 ± 42.6HDL-C, mg/dL*n* = 2416*n* = 1120*n* = 607*n* = 689\<0.00152.2 ± 17.754.8 ± 19.251.8 ± 16.648.4 ± 15.0Triglycerides, mg/dL*n* = 2392*n* = 1104*n* = 602*n* = 686\<0.001172.4 ± 101.0150.6 ± 78.3193.1 ± 117.3189.5 ± 110.5Systolic blood pressure, mmHg*n* = 2503*n* = 1161*n* = 629*n* = 713\<0.001133.3 ± 13.3131.5 ± 13.3135.1 ± 12.9134.7 ± 13.4Diastolic blood pressure, mmHg*n* = 2497*n* = 1160*n* = 627*n* = 710\<0.00179.6 ± 8.479.0 ± 8.280.7 ± 8.679.5 ± 8.6HbA1c, %*n* = 1658*n* = 346*n* = 620*n* = 692\<0.0016.6 ± 1.45.2 ± 1.87.0 ± 1.07.0 ± 1.0Fasting glucose, mg/dL*n* = 2040*n* = 799*n* = 574*n* = 667\<0.001115.4 ± 37.991.6 ± 19.7127.5 ± 38.1133.5 ± 39.3All values are mean ± standard deviation, if not indicated otherwise*P* values were calculated by Kruskal--Wallis test*CHD* coronary heart disease, *DM* diabetes mellitus

Mean systolic blood pressure was 133.3 ± 13.3 mmHg, and diastolic blood pressure 79.6 ± 8.4 mmHg. The mean systolic value was lower in the CHD group compared to the other subgroups, while the mean diastolic values were similar across groups.

LDL-C target level achievement {#Sec9}
------------------------------

The distribution of LDL-C values in the total cohort is shown in Fig. [1](#Fig1){ref-type="fig"}. The LDL-C target value of \<70 mg/dL was achieved only by 10.5 % of the patients overall. The rate was lowest in the DM group (7.5 %) and somewhat higher in the CHD group (9.3 %) and the DM + CHD group (15.2 %), respectively (Fig. [2](#Fig2){ref-type="fig"} top).Fig. 1Histogram of LDL-C categories at the documentation visit. *P* \< 0.001 (Chi-square test) each for the comparison of the CHD, DM and CHD + DM groups with respect to LDL-C \<70 mg/dL, or with respect to treating physician's assessmentFig. 2LDL-C target attainment by laboratory results (\<70 mg/dL) and subjective physician assessment. *Figure* shows the percentages of patients with LDL-C \<70 mg/dl (*blue bars*) and in comparison the percentages of patients that were judged by their physicians to have clinically met their individual LDL-C target

Target level achievement rates were not associated with the duration of atorvastatin treatment. Patients who met the LDL-C target compared to those who did not had similar treatment duration (93.1 ± 96.3 versus 92.7 ± 111.3 weeks).

The distribution of atorvastatin dosage categories (mg/day) was similar across all LDL-C categories (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Distribution of atorvastatin dosages by LDL-C category. The distribution of atorvastatin dosage categories (mg/day) was similar across all LDL-C categories

The subjective physician assessment of target achievement substantially deviated from the laboratory values. While 10.5 % of patients who had not achieved the target according to the LDL-C criterion (\<70 mg/dL), 62.7 % were assessed by their physicians to have clinically met the target (Fig. [2](#Fig2){ref-type="fig"} bottom).

Overall, 74.3 % of physicians were satisfied with the atorvastatin therapy, with marginal differences across subgroups. However, satisfaction decreased with increasing atorvastatin dose: 78.8 % of physicians were satisfied with the 10 mg/day dose in contrast to 63.2 % with the 80 mg/day dose.

Discussion {#Sec10}
==========

The two main findings of this contemporary cross-sectional analysis are that patients at very high cardiovascular risk treated with atorvastatin receive relatively low doses and that only a minority of the patients achieved an LDC-C below \<70 mg/dL.

Lipid abnormalities are highly prevalent under clinical practice conditions \[[@CR6], [@CR9], [@CR10], [@CR12], [@CR37]\]. Despite the documented benefit of statin therapy and the consensus of the guidelines on intensive treatment for high-risk patients, the standard of care documented in this large contemporary sample reveals a substantially different situation. The incomplete implementation of guideline recommendations supports data from US office-based cardiologists who did not use statins in 32.4 % of those patients who were eligible for such medication \[[@CR21]\]. In other countries similar findings were reported \[[@CR34], [@CR35]\]. In the EUROASPIRE IV study in 76 centers of 24 European countries an improved situation in the management of CHD patients was shown: at least on the short term statins were administered to 85.7 % of eligible patients (with or without other cardioprotective medications) \[[@CR18]\]. This represents a clear improvement to an earlier study in Germany, in which the treatment rates with statins (and other cardioprotective medications) decreased substantially over time: after 5 years only 17 % of eligible patients, who originally had received statins, were still on such agents \[[@CR22]\]. Our study now provides evidence that even in the patients that receive a potent statin, a majority of patients receives a low dose.

Atorvastatin, introduced in 1996, is a well-studied statin with high potency to lower elevated LDL-C levels. It is prescribed to a large portion of statin-treated patients around the world. Data from randomized trials suggest that the full dose of 80 mg atorvastatin can lower LDL-C by 45--55 % \[[@CR19], [@CR25], [@CR29]\]. Indeed, for atorvastatin the "fire and forget strategy" was propagated based on the assumption owing to its strong LDL-C lowering effect the drug would not require follow-up examination \[[@CR4]\]. However, this assumption only applies for the drug given at high doses \[[@CR33]\]. In an analysis of the VOYAGER database, 40 or 59 % of patients on atorvastatin 40 or 80 mg/day achieved more than 50 % decrease of LDL-C \[[@CR15]\]. This strong lowering of LDL-C by atorvastatin was associated with a reduction of major coronary events across all investigated risk groups \[[@CR26]\].

To our knowledge, current observational data on atorvastatin use and effectiveness in clinical practice is limited to two reports. In the UK, of 2999 high-risk patients (60.2 % men; mean age 67.9 ± 10.6 years), 23.9, 28.2, 36.2, and 11.6 % were administered atorvastatin 10, 20, 40, and 80 mg, respectively \[[@CR14]\]. Across all doses, the mean LDL-C level was 81 ± 27 mg/dL, and 46.5 % had LDL-C \<77 mg/dL \[[@CR14]\]. In an analysis of chart reviews of two health insurance databases, 21.8, 29.6, 29.9, and 18.7 % (GE Centricity EMR) and 25.4, 32.9, 27.8, and 14.0 % (Humana Medicare) received 10, 20, 40, and 80 mg/day doses of atorvastatin, respectively \[[@CR24]\]. The mean follow-up LDL-C levels were 83 ± 30 and 88 ± 31 mg/dL for the GE Centricity EMR and Humana Medicare cohorts, respectively. Regardless of dose, only 28.3--34.8 % of patients had LDL-C \<70 mg/dL \[[@CR24]\].

Our data show a mean LDL-C level of 116.3 mg/dL. Importantly, only 10.5 % of patients reached LDL-C values below 70 mg/dL. These findings confirm earlier reports from clinical practice suggesting that physicians are reluctant to administer high atorvastatin doses. Registries such as DYSIS \[[@CR2]\] and 2L \[[@CR11]\] report simvastatin doses in the lower or intermediate range. DISCOVER did not investigate reasons for the preference for low atorvastatin doses. It is possible that physicians want to avoid side effects associated with higher doses. Indeed, muscle-related adverse events, cognitive and memory problems, and increase of liver enzymes have been reported to occur more frequently at higher doses \[[@CR8], [@CR30]\]. Generally a 5--10 % rate of treatment-associated adverse events is associated with statin use in randomised clinical trials. \[[@CR16]\] Under clinical practice conditions, the observed rates appear to be higher, probably owing to the higher proportion of patients with various comorbidities, with complex concomitant medication patterns or further factors that might complicate pharmacotherapy (such as alcohol consumption) \[[@CR23]\]. For example, in a study in Boston, 17.4 % of patients reported side effects, and 53.1 % had at least one therapy interruption \[[@CR38]\]. Other possible explanations include a lack of awareness/communication of the clinical trial data and the respective guidelines.

Our analysis showed that patients with concomitant CHD and DM were better managed in terms of LDL-C goal attainment, and treated with higher atorvastatin doses compared to patients who had only one of these conditions. This finding is in line with earlier studies in Germany and other countries that showed that patients with cardiovascular conditions are treated more intensively at a later stage of the disease, after complications have occurred \[[@CR1], [@CR32]\].

Limitations {#Sec11}
-----------

The current study collected data retrospectively at one time point. However, the majority of patients were under maintenance therapy which allows a reliable snapshot of the current situation. In prospective observational studies, the rate of patients with achieved target values usually increases between the inclusion and the follow-up visits. This might be due to the study situation, but also due to the feedback of target values for the individual patient. DISCOVER used various quality measures and plausibility checks, included patients in all regions of Germany, and stipulated the consecutive inclusion of eligible patients at the sites. Site selection focused on those physicians who usually make treatment decisions on statin use. General practitioners/family physicians, internists and cardiologists accounted for 64.7, 26.2 and 6.7 % in our study. The shares of these physician groups among all active German physicians are 42.0, 10.2, and 1.2 %, respectively \[[@CR3]\]. As only few inclusion/exclusion criteria applied, typical patients under real life conditions were documented including those with comorbidities and concomitant medication. Notably, in non-participating centers and non-participating patients the situation may be different, as those willing to participate may be more adherent to guideline-oriented therapy compared to those declining. No data on medication adherence to statins were collected \[[@CR7]\]; however, use of generic drugs compared to the originals likely plays no major role for adherence \[[@CR28]\]. Lastly, the LDL-C levels of patients before the initiation of drug treatment were not known, but would have been of interest to assess the percentage lipid-lowering effect of atorvastatin compared to the situation in the untreated patient.

In conclusion, LDL-C target achievement rates as stipulated by current EAS/ESC guidelines for high-risk individuals under conditions of current clinical practice often were not met despite treatment with the potent lipid-lowering drug atorvastatin. Atorvastatin was prescribed at relatively low doses (mean 28 mg/day). Only one in ten patients on atorvastatin reached the LDL-C target of \<70 mg/dL, which is substantially less than rates achieved in other countries. Physicians very often stated that their patients had achieved their individual lipid targets which were in stark contrast to the low achievement rates as evidenced by objective measurements of LDL-C values. Better communication of clinical evidence and the guidelines appears to be needed. Improved lipid management of these high cardiovascular risk patients can be achieved by using higher doses of potent statins and/or combination therapy.

The statistical analysis was performed by Winicker Norimed GmbH, Nürnberg, Germany. The study was funded by MSD.
